

Qualified in Maryland (US) & Illinois (US) & Washington DC (US) & New York (US), 1992
Partner for 9 years
Litigation
Patent Litigation
Healthcare & Life Sciences
Intellectual Property
Elizabeth Stotland Weiswasser is a Partner at Paul, Weiss in New York City, where she co-chairs the Litigation Department. Renowned for her expertise in life sciences litigation, Liz represents leading pharmaceutical, biotechnology, and medical device companies in complex patent disputes. With a strong background in molecular biology and biochemistry, she excels in handling cases involving biologics, small molecules, and drug delivery technologies. Liz is recognized for her strategic insights and client-focused approach, making her a sought-after litigator in the industry. She is licensed before the U.S. Patent Office and has extensive experience in federal courts and post-grant review proceedings.

- Alkermes plc acquired the target/assets from Avadel Pharmaceuticals plc in an acquisition. Date not available. - Deal value was 2100000000. Sector: Biopharmaceuticals; Location: not available. - On the acquirer side, legal advice was provided by a team including Chelsea Darnell, James Langston, Timothy Cruickshank, Daniel Gerkin, Nathan Mitchell, Matthew Friestedt, Jeffrey Osterman, John Patten, Matthew Rosenberg, Alex Zapalowski, Brian Krause, Geoffrey Chepiga, Elizabeth Weiswasser, Audrey Paquet, Natalie Kennedy, Nicole Kar, Scott Sher, John Magruder.
Oct 22 2025
2B
M&A

Partner
2024 – Unknown
Partner
2016 – 2024



- Eli Lilly and Company acquired Verve Therapeutics, Inc. from Verve Therapeutics, Inc. in a acquisition on 2025-06-17. - Deal value was 10000000000 (source: Extracted) Ownership: 100% acquisition; Sector: Healthcare; Location: USA. - On the acquirer side, Kirkland & Ellis advised, led by Keri Schick Norton, Sarkis Jebejian, Steven Choi.
Jun 17 2025
1B
M&A
Oct 21
2 min
B.A. in Biochemistry and Molecular Biology, Northwestern University